Ambulero Inc

Ambulero Inc. is a privately held biotechnology company located in Miami, Florida. Founded as a spin-out of the University of Miami, Ambulero employs five individuals and generates annual revenue of $2.5 million. Ambulero specializes in developing innovative cell and gene therapies aimed at treating vascular diseases. Their focus lies in advancing therapies utilizing the adhesion molecule E-selectin, delivered through various cell-based and synthetic vector technologies. Ambulero's research targets both rare vascular diseases and more common conditions impacting substantial patient populations. Ambulero distinguishes itself as a platform company, leveraging its expertise in E-selectin delivery to tackle a wide range of vascular disease challenges. Their adaptable approach allows them to explore diverse therapeutic avenues, ultimately aiming to improve patient outcomes. For inquiries or further information, please visit Ambulero's website at ambulero.com.